2025 – Talk Bio

2025 FDA staff cuts and their impact on new drug review timelines

3 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

3 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

3 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

3 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

FDA Policy Tracker: 2025 Was a Year of Change

3 weeks ago talkbio0Tagged 2025, Drug Approval, Food Safety, GRAS Reform, Improvements, Mental Recall, Trump administration, United States Food and Drug Administration

FDA; 2025; Trump Administration; Food Safety; FSMA 204; GRAS Reform; Drug Approvals; Recall Improvements

Spotlight On: Five Key FDA Approvals of 2025

1 month ago talkbio0Tagged 2025, approvals, Drugs, Orphan, Infrequent, United States Food and Drug Administration

FDA approvals; 2025; orphan drugs; novel therapies; rare diseases

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

1 month ago talkbio0Tagged 2025, Biopharma, Endpoints, Kyle LaHucik, Losers, movers, News [Publication Type], Pharma, Post-Hoc Live, Review [Publication Type], winners

Endpoints News; winners and losers; 2025; biopharma; Post-Hoc Live; Kyle LaHucik; year in review; biotech; pharma; stock movers

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

1 month ago talkbio0Tagged 2025, Acquisition, Acquisitions, fibroblast growth factor 21, Health care facility, Johnson & Johnson Intra-Cellular, M&A, MASH, Merck Verona, Patent Cliff, Pharma, pharma patent expirations, Sanofi Blueprint Medicines

pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals

The 5 Most Painful Clinical Trial Failures of 2025

1 month ago talkbio0Tagged 2025, approvals, Clinical Trial Failures, gene therapy, Mississippi (geographic location), Muscular Dystrophy, Duchenne, United States Food and Drug Administration

clinical trial failures; 2025; biotech; gene therapy; MS; DMD; FDA approvals

Health tech investors are getting creative with exits in 2025

2 months ago talkbio0Tagged 2025, AI healthtech IPOs, Exit, healthtech, Investments, M&A consolidation, Private Equity, provider operations, roll-ups, secondary markets, trends qualifier, Vital capacity

healthtech exits 2025; creative exit strategies; M&A consolidation; secondary markets; private equity roll-ups; AI healthtech IPOs; provider operations investment; VC healthtech trends